Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCNN1A | P37088 | 15/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13732176 | 0.90 | SCNN1A (0.43) | SCNN1A | |
| SCHEMBL10115663 | 0.90 | SCNN1A (0.43) | SCNN1A | |
| SCHEMBL705437 | 0.89 | SCNN1A (0.44) | SCNN1A | |
| SCHEMBL709780 | 0.89 | SCNN1A (0.46) | SCNN1A | |
| Hydrochloric Acid SCHEMBL708001 | 0.89 | SCNN1A (0.43) | SCNN1A | |
| SCHEMBL23182831 | 0.87 | SCNN1A (0.44) | SCNN1A | |
| SCHEMBL19606901 | 0.87 | SCNN1A (0.41) | SCNN1A | |
| SCHEMBL709258 | 0.87 | SCNN1A (0.41) | SCNN1A | |
| SCHEMBL709779 | 0.87 | SCNN1A (0.38) | SCNN1A | |
| SCHEMBL15807601 | 0.85 | SCNN1A (0.39) | SCNN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2931711-B1 | ARYLALKYL-AND ARYLOXYALKYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | PARION SCIENCES INC (US) | 2017-08-02 | — | — | EP | disclosed |
| US-9102633-B2 | Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds | PARION SCIENCES, INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-20150166488-A1 | ARYLALKYL- AND ARYLOXYALKYL-SUBSTITUTED EPTHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | PARION SCIENCES, INC. (US) | 2015-06-18 | — | — | US | disclosed |
| US-20150166487-A1 | ARYLALKYL- AND ARYLOXYALKYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | PARION SCIENCES, INC. (US) | 2015-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166488-A1 | ARYLALKYL- AND ARYLOXYALKYL-SUBSTITUTED EPTHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | CFTR, SCNN1B, SCNN1A | SCNN1A 3/4885 |
| US-20150166487-A1 | ARYLALKYL- AND ARYLOXYALKYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | CFTR, SCNN1B, SCNN1A | SCNN1A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.